Seattle Genetics To Introduce More Cancer Drugs
Clay B. Siegall is a biotechnology expert who is based in the United States. He is currently the Chief Executive Officer of a company he founded in 1998, known as Seattle Genetics. Clay is also the institutions’ Chairman in the board of directors. Clay is a scientist by training, and he specializes in cancer treatments. The researcher used these skills to start Seattle Genetics, and today it is recognized as one of the best drug development companies in the country. He has a passion for helping cancer patients and this explains his vigorous research in the industry.
Since 1998, Dr. Clay Siegall has worked hard to guide his company to its current position. The company has managed to develop antibody drugs conjugates. Its first drug is known Adcetris, and it was introduced in the market several years ago. In the year 2011, the drug was approved by the FDA. At the moment, the drug is being used internationally, and it is approved in over sixty nations around the globe. The pharmacist was recently appointed to join Mirna Therapeutics as the as one of the directors.
This year, the vice president of the country, Joe Biden visited the company. During the tour, the company announced its plans to advance its treatment for different types of cancer. Under the leadership of Clay Siegall, the international company announced that it was entering into various strategic licenses for in the ADC technology. To make sure that the dream comes right, Clay Siegall has worked hard to raise capital. In the recent past, the company has been involved in capital-raising activities, and it managed to secure over one billion dollars the private and public financing. The initial public offering from the company took place in the year 2001, and it was very successful.
After the successful fund raising activities, Clay Siegall announced that his company would be increased its employees to cater to the increasing number of requirements for Seattle Genetics. The company is planning to develop over twelve drugs in five years to cure different types of cancers that are common in the recent times. Some of the drugs from the company will be used for curing breast cancer.